Janssen-cilag G.m.b.h

This study follows 400 people with Crohn's disease or ulcerative colitis who are starting guselkumab, a biologic drug. Researchers will measure how many achieve remission and how the drug affects fatigue, quality of life, and daily activities. The goal is to see how well the trea…